Key result
Dexrazoxane inhibits neonatal rat ventricular myocyte division and induces endopolyploidy via DNA topoisomerase II inhibition.
Why the study?
Dexrazoxane is used clinically to reduce doxorubicin-induced cardiotoxicity and is a potent catalytic inhibitor of DNA topoisomerase II, but its effects on cardiac myocyte division were unclear.
Does dexrazoxane induce endopolyploidy in rat neonatal myocytes through inhibition of DNA topoisomerase II?
Does dexrazoxane induce endopolyploidy in rat neonatal myocytes through inhibition of DNA topoisomerase II?
Dexrazoxane interferes with cell division in cardiac myocytes by inhibiting topoisomerase II, leading to endopolyploidy.
Answers are grounded in this paper and cite their sources.
Should not change dexrazoxane use; leaves open relevance of neonatal rat myocyte findings to adult human hearts.
Dexrazoxane (ICRF-187), which is clinically used to reduce doxorubicin-induced cardiotoxicity, is also a potent catalytic inhibitor of DNA topoisomerase II. In this study we showed that dexrazoxane inhibited the division of neonatal rat ventricular myocytes in culture, and resulted in nuclear multilobulation (demonstrated by three-dimensional reconstruction of confocal images) and marked increases in nuclear size and DNA ploidy levels (as shown by flow cytometry). It was concluded that dexrazoxane interfered with cell division in cardiac myocytes by virtue of its ability to inhibit topoisomerase II.
No takes yet. Share an insight, caveat, or question.
Hasinoff et al. (2002) studied this question. Dexrazoxane (ICRF-187) was evaluated on Cell division, nuclear multilobulation, nuclear size, and DNA ploidy levels. Dexrazoxane inhibited the division of neonatal rat ventricular myocytes in culture and induced endopolyploidy through inhibition of DNA topoisomerase II.
Synapse has enriched 10 related papers. Consider them for comparative context: